Drug Profile
VR 096 - Janssen Biotech/Vectura
Alternative Names: VR096Latest Information Update: 10 Sep 2018
Price :
$50
*
At a glance
- Originator Janssen Biotech; Vectura
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 10 Sep 2018 No development reported - Phase-II for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 05 Sep 2018 No development reported - Phase-II for Asthma in United Kingdom (Inhalation)
- 06 Jan 2015 Vectura and Janssen enter into a global development and license agreement to develop anti-inflammatory therapies for Asthma and Chronic obstructive pulmonary disease